862874-67-7

Usage

Uses

Used in Pharmaceutical Industry:
Pyrrolidine, 1-[2-(2-chloro-4-nitrophenoxy)ethyl]is used as a building block for the synthesis of complex organic compounds that may have therapeutic uses. Its unique molecular structure allows it to be a valuable component in the development of new pharmaceuticals.
Used in Agrochemical Industry:
In the agrochemical industry, Pyrrolidine, 1-[2-(2-chloro-4-nitrophenoxy)ethyl]is utilized as a component in the development of various agrochemical products. Its potential applications may include the creation of new pesticides or herbicides.
Used in Organic Synthesis:
Pyrrolidine, 1-[2-(2-chloro-4-nitrophenoxy)ethyl]is used as a key intermediate in organic synthesis, contributing to the formation of a wide range of organic compounds for various purposes.
It is crucial to handle Pyrrolidine, 1-[2-(2-chloro-4-nitrophenoxy)ethyl]with care and follow safety protocols due to its potential hazards.

Upstream product

• 619-08-9 2-chloro-4-nitrophenol 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 2955-88-6 1-pyrrolidineethanol 
• 350-30-1 3-chloro-4-fluoronitrobenzene 

Downstream Products

• 862874-68-8 3-chloro-4-(2-(pyrrolidin-1-yl)ethoxy)aniline 

Relevant academic research and scientific papers

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: Design, synthesis and 3D-QSAR studies

VEGFR-2 plays an essential role in angiogenesis and is a central target for anticancer drug discovery. In order to develop novel VEGFR-2 inhibitors, we designed and synthesized 33 biphenyl amides based on our previously reported lead compound. The biological results indicated that four compounds (18b, 20e, 20h and 20j) are potent VEGFR-2 inhibitors which are comparable to positive control. Compound 18b displayed the most potent VEGFR-2 inhibition with IC50 value of 2.02 nM. Moreover, it exhibited promising antiproliferative activity against MCF-7 and SMMC-7721 cells with IC50 values of 1.47 μM and 5.98 μM, respectively. Molecular docking and 3D-QSAR studies were also carried out. The results indicated that these biphenyl amides could serve as promising leads for further optimization as novel VEGFR-2 inhibitors.

PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.

THIAZOLE AND OXAZOLE KINASE INHIBITORS

The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

THIAZOLE AND OXAZOLE KINASE INHIBITORS

The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R1, q, p, R2, t, Ar1, L1, R3 and R4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

BISARYLUREA DERIVATIVES

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.